GSK and Dynavax in potential $810 million inflammatory disease deal
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline and Dynavax Technologies are to develop novel endosomal Toll-like receptors (TLRs) against inflammatory diseases in a deal worth up to $810 million.